New York City, NY, August 30, 2017/24 Market Reports: Alpha-Synuclein is a protein normally found in cells all over the body. It is one of the key players in Parkinson‘s. In Parkinson‘s it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It reduces neuronal responsiveness to various apoptotic stimuli, leading to decreased caspase-3 activation.
Alpha Synuclein (Non A Beta Component of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) pipeline Target constitutes close to 37 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 5, 21, 2 and 1 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively. Report covers products from therapy areas Central Nervous System, Metabolic Disorders, Cardiovascular, Gastrointestinal, Infectious Disease and Ophthalmology which include indications Parkinson's Disease, Alzheimer's Disease, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), Neurodegenerative Diseases, Lewy body Dementia, Amyloidosis, Constipation, Familial Amyloid Neuropathies, Glaucoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Huntington Disease, Schizophrenia, Spinal Cord Injury, Stroke, Traumatic Brain Injury and Type 2 Diabetes.
The latest report of Alpha Synuclein Pipeline Review, H2 2017, outlays comprehensive information on the Alpha Synuclein Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Alpha Synuclein Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA targeted therapeutics development with respective active and dormant or discontinued projects.
Source: 24 Market Reports